Significant predictors of pathological response include HER2 protein overexpression by IHC, grade 3 histology, PR-negative status, and dual anti-HER2 therapy. Additional studies are needed to ...

Most of the literature reports a correlation between HER-2 overexpression and increased sensitivity to anthracycline-based chemotherapy in comparison with CMF and tamoxifen (Elledge et al ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

IBI354 has demonstrated promising anti-tumor efficacy and favorable safety profiles across multiple solid tumors. It not only holds potential to deliver a new generation of ADC therapies characterized ...

HER-2/neu Overexpression and Response to Oophorectomy Plus Tamoxifen Adjuvant Therapy in Estrogen Receptor-Positive Premenopausal Women With Operable Breast Cancer Purpose: Human epidermal growth ...

Because HER2 status is important in understanding how aggressive a tumor might be—and how best to treat it—testing should be performed on the biopsy or surgery sample of all newly diagnosed ...

On the other hand, the MyPathway study used any clear certified test that showed HER2 amplification or overexpression, similar to the MOUNTAINEER study, and they showed response rates of anywhere ...

This leads to too many HER2 proteins in your breast cells, a situation called "protein overexpression." The result is breast cells that divide and grow too quickly. Special tests help your doctor ...

Ciombor estimated that 1 in 5 patients has metastatic disease at the time of diagnosis. Some 50% of patients with stage III disease who receive surgery alone eventually have a recurrence; the ...

HER2 classification relies on immunohistochemistry ... HER2 assays are semiquantitative and were optimized to detect HER2 overexpression. Furthermore, some data suggest that IHC 0 cancers respond ...

Researchers at ASCO provided a look at DB-1310 and iza-bren in genomically altered NSCLC, amid an overall survival miss for ...

HER2 overexpression or amplification is a known poor prognostic indicator in various malignancies and has been previously studied in EMPD, albeit with limited sample sizes. The rates of HER2 ...